JP2008534606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534606A5 JP2008534606A5 JP2008504396A JP2008504396A JP2008534606A5 JP 2008534606 A5 JP2008534606 A5 JP 2008534606A5 JP 2008504396 A JP2008504396 A JP 2008504396A JP 2008504396 A JP2008504396 A JP 2008504396A JP 2008534606 A5 JP2008534606 A5 JP 2008534606A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- amount effective
- amylin
- overeating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66668105P | 2005-03-31 | 2005-03-31 | |
| US66733505P | 2005-03-31 | 2005-03-31 | |
| US60/666,681 | 2005-03-31 | ||
| US60/667,335 | 2005-03-31 | ||
| US67544105P | 2005-04-28 | 2005-04-28 | |
| US60/675,441 | 2005-04-28 | ||
| US76058306P | 2006-01-20 | 2006-01-20 | |
| US60/760,583 | 2006-01-20 | ||
| PCT/US2006/011768 WO2006105345A2 (en) | 2005-03-31 | 2006-03-31 | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534606A JP2008534606A (ja) | 2008-08-28 |
| JP2008534606A5 true JP2008534606A5 (enExample) | 2009-05-14 |
| JP5415067B2 JP5415067B2 (ja) | 2014-02-12 |
Family
ID=37054153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504532A Expired - Fee Related JP5114381B2 (ja) | 2005-03-31 | 2006-03-31 | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
| JP2008504396A Expired - Fee Related JP5415067B2 (ja) | 2005-03-31 | 2006-03-31 | 肥満および摂食障害の制御、防止および治療のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504532A Expired - Fee Related JP5114381B2 (ja) | 2005-03-31 | 2006-03-31 | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7671023B2 (enExample) |
| EP (5) | EP1888094B1 (enExample) |
| JP (2) | JP5114381B2 (enExample) |
| KR (3) | KR20080003849A (enExample) |
| CN (3) | CN101189021B (enExample) |
| AT (2) | ATE480255T1 (enExample) |
| AU (2) | AU2006230602B2 (enExample) |
| BR (2) | BRPI0609595A8 (enExample) |
| CA (2) | CA2602584A1 (enExample) |
| DE (2) | DE602006008456D1 (enExample) |
| DK (1) | DK1888094T3 (enExample) |
| EA (1) | EA013121B1 (enExample) |
| ES (1) | ES2330671T3 (enExample) |
| IL (1) | IL186200A (enExample) |
| MX (2) | MX2007012237A (enExample) |
| NZ (3) | NZ578298A (enExample) |
| WO (2) | WO2006105527A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| EP2233497A3 (en) * | 2004-02-11 | 2011-01-12 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006105527A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| WO2007014051A2 (en) * | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| WO2007104789A2 (en) | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| CA2647568A1 (en) * | 2006-03-31 | 2007-10-11 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| WO2007140416A2 (en) | 2006-05-30 | 2007-12-06 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
| PT2359808E (pt) | 2006-08-09 | 2013-08-28 | Intarcia Therapeutics Inc | Sistemas de entrega osmótica e montagens de pistão |
| ES2389747T3 (es) | 2007-02-05 | 2012-10-31 | Amylin Pharmaceuticals, Inc. | Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad |
| ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| JP2011525895A (ja) * | 2008-06-25 | 2011-09-29 | ノボ・ノルデイスク・エー／エス | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド |
| WO2010046357A1 (en) * | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
| EP2389388B1 (en) * | 2009-01-22 | 2017-03-08 | KeyBioscience AG | Treatment for obesity |
| EP2416797A4 (en) * | 2009-04-10 | 2013-04-24 | Amylin Pharmaceuticals Llc | AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| BRPI1013856A2 (pt) | 2009-04-20 | 2016-04-05 | Elcelyx Therapeutics Inc | terapias à base de ligantes de receptores quimiossensíveis |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| EP3735944A1 (en) | 2009-09-28 | 2020-11-11 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| WO2012000166A1 (zh) | 2010-06-28 | 2012-01-05 | 中兴通讯股份有限公司 | 一种全封闭式综合接入系统及其降功耗的方法 |
| WO2012054523A2 (en) | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| LT2661266T (lt) | 2011-01-07 | 2020-12-10 | Anji Pharma (Us) Llc | Gydimo būdai chemosensorinio receptoriaus ligando pagrindu |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| AU2012270366C1 (en) * | 2011-06-17 | 2017-07-13 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| CN104254325A (zh) | 2012-01-06 | 2014-12-31 | 埃尔舍利克斯治疗公司 | 双胍组合物和治疗代谢性病症的方法 |
| MX347229B (es) | 2012-01-26 | 2017-04-19 | Christopher J Soares | Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
| JP6538682B2 (ja) * | 2013-07-30 | 2019-07-03 | ソアレス クリストファー ジェイ． | Ｃｇｒｐアゴニストペプチド |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| KR102650751B1 (ko) | 2015-06-03 | 2024-03-22 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
| CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| ES2965087T3 (es) | 2016-09-02 | 2024-04-10 | Soares Christopher J | Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma |
| AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
| EP3568411B1 (en) * | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
| EP3628233B1 (en) * | 2018-09-28 | 2021-06-02 | Siemens Healthcare GmbH | Method and system for providing a dose reference value for a patient |
| US11443843B2 (en) | 2019-01-04 | 2022-09-13 | International Business Machines Corporation | Personal customized guidance for treating patients |
| CN113631157A (zh) | 2019-02-17 | 2021-11-09 | 诺拉威尔治疗公司 | 用于治疗抑郁症和其它病症的组合物和方法 |
| CN111700904A (zh) * | 2020-07-31 | 2020-09-25 | 江南大学 | 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法 |
| EP4366755A4 (en) * | 2021-07-08 | 2025-09-24 | Gila Therapeutics Inc | COMPOSITIONS AND METHODS FOR ACTIVATING A NEURAL RECEPTOR |
| TW202530247A (zh) * | 2023-12-04 | 2025-08-01 | 丹麥商西蘭製藥公司 | 方法 |
| TW202528338A (zh) * | 2023-12-04 | 2025-07-16 | 丹麥商西蘭製藥公司 | 方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3065460D1 (en) | 1979-07-28 | 1983-12-08 | Beecham Group Plc | Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US4397780A (en) | 1982-02-12 | 1983-08-09 | Armour Pharmaceutical Company | Leucine22 -calcitonin |
| US4401593A (en) | 1982-02-12 | 1983-08-30 | Armour Pharmaceutical Company | Glycine - 8 calcitonin |
| US4414149A (en) | 1983-03-04 | 1983-11-08 | Armour Pharmaceutical Company | Glycine8 -D-arginine24 calcitonin |
| US4497731A (en) | 1983-04-04 | 1985-02-05 | Armour Pharmaceutical Company | Glycine 8-des-tyrosine 22 calcitonin |
| US4495097A (en) | 1983-04-04 | 1985-01-22 | Armour Pharmaceutical Company | Des-serine2 -glycine8 calcitonin |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| US4597900A (en) | 1983-08-22 | 1986-07-01 | Armour Pharmaceutical Co. | Des2 -glycine8 -des22 -calcitonin |
| US4537716A (en) | 1983-12-05 | 1985-08-27 | Armour Pharmaceutical Co. | Des-serine2 or des-glycine2 -leucine22 calcitonin |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US4604238A (en) | 1984-12-10 | 1986-08-05 | Armour Pharmaceutical Company | Analogs of calcitonin |
| US4606856A (en) | 1985-03-18 | 1986-08-19 | Seyler Jay K | [Des-1-amino, 8-glycine]calcitonin |
| US4652627A (en) | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
| US4697002A (en) | 1985-12-23 | 1987-09-29 | Kempe Tomas G | Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36 |
| US4687839A (en) | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5405831A (en) | 1989-07-08 | 1995-04-11 | Amylin Pharmaceuticals, Inc. | Treatment of bone disorders |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| SK88793A3 (en) | 1991-11-19 | 1994-12-07 | Amylin Pharmaceuticals Inc | Amylin agonising peptides and their using |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
| US5589356A (en) | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
| AU7685894A (en) * | 1993-09-07 | 1995-03-27 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| US6307018B1 (en) | 1996-12-24 | 2001-10-23 | The Scripps Research Institute | General chemical ligation |
| JP4798814B2 (ja) | 1997-01-07 | 2011-10-19 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 食物摂取低減用のエキセンジンおよびそのアゴニストの使用 |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| WO1998056807A1 (en) | 1997-06-13 | 1998-12-17 | Gryphon Sciences | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
| EP1091440B1 (en) | 1998-05-29 | 2010-06-02 | JGC Catalysts and Chemicals Ltd. | Method of manufacturing photoelectric cell |
| US6087334A (en) * | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| AU763092B2 (en) | 1998-08-31 | 2003-07-10 | Gryphon Sciences | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| AU2001273385B2 (en) | 2000-09-08 | 2005-04-07 | Gryphon Therapeutics, Inc. | Polymer-modified synthetic proteins |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
| EP1456225A2 (en) | 2001-11-14 | 2004-09-15 | Geneprot, Inc. | Extended native chemical ligation of three or more peptide fragments |
| NZ534557A (en) | 2002-01-08 | 2007-10-26 | Amylin Pharmaceuticals Inc | Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels |
| TWI281914B (en) * | 2002-05-29 | 2007-06-01 | Glaxo Group Ltd | Compounds |
| EP1511760B1 (en) | 2002-06-10 | 2006-01-18 | Geneprot, Inc. | Carboxy protection strategies for acidic c-terminal amino acids in chemical ligation of oligopeptides |
| US6965013B2 (en) | 2002-11-26 | 2005-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| US20060275768A1 (en) | 2002-12-30 | 2006-12-07 | Kochendoerfer Gerd G | Multiplex polymer ligation |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| EP1631597A4 (en) | 2003-05-22 | 2007-07-11 | Gryphon Therapeutics Inc | SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT |
| EP2233497A3 (en) | 2004-02-11 | 2011-01-12 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| AU2005295043A1 (en) | 2004-10-08 | 2006-04-20 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them |
| WO2006105527A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
-
2006
- 2006-03-31 WO PCT/US2006/012601 patent/WO2006105527A2/en not_active Ceased
- 2006-03-31 CA CA002602584A patent/CA2602584A1/en not_active Abandoned
- 2006-03-31 EP EP06749305A patent/EP1888094B1/en active Active
- 2006-03-31 CN CN2006800192236A patent/CN101189021B/zh not_active Expired - Fee Related
- 2006-03-31 BR BRPI0609595A patent/BRPI0609595A8/pt not_active IP Right Cessation
- 2006-03-31 EP EP10008733A patent/EP2248527A3/en not_active Withdrawn
- 2006-03-31 DE DE602006008456T patent/DE602006008456D1/de active Active
- 2006-03-31 AT AT06740117T patent/ATE480255T1/de not_active IP Right Cessation
- 2006-03-31 JP JP2008504532A patent/JP5114381B2/ja not_active Expired - Fee Related
- 2006-03-31 AT AT06749305T patent/ATE439140T1/de active
- 2006-03-31 AU AU2006230602A patent/AU2006230602B2/en not_active Ceased
- 2006-03-31 US US11/910,206 patent/US7671023B2/en not_active Expired - Fee Related
- 2006-03-31 NZ NZ578298A patent/NZ578298A/en not_active IP Right Cessation
- 2006-03-31 JP JP2008504396A patent/JP5415067B2/ja not_active Expired - Fee Related
- 2006-03-31 KR KR1020077025124A patent/KR20080003849A/ko not_active Abandoned
- 2006-03-31 KR KR1020137025456A patent/KR20130122983A/ko not_active Ceased
- 2006-03-31 EP EP10008998.6A patent/EP2258382A3/en not_active Withdrawn
- 2006-03-31 MX MX2007012237A patent/MX2007012237A/es active IP Right Grant
- 2006-03-31 DE DE602006016760T patent/DE602006016760D1/de active Active
- 2006-03-31 BR BRPI0606466-3A patent/BRPI0606466A2/pt not_active IP Right Cessation
- 2006-03-31 EA EA200702126A patent/EA013121B1/ru not_active IP Right Cessation
- 2006-03-31 NZ NZ578299A patent/NZ578299A/en not_active IP Right Cessation
- 2006-03-31 EP EP09009392.3A patent/EP2135617A3/en not_active Withdrawn
- 2006-03-31 US US11/910,214 patent/US7879794B2/en not_active Expired - Fee Related
- 2006-03-31 CN CN2011102204917A patent/CN102343084A/zh active Pending
- 2006-03-31 AU AU2006230420A patent/AU2006230420B2/en not_active Ceased
- 2006-03-31 CA CA002602261A patent/CA2602261A1/en not_active Abandoned
- 2006-03-31 ES ES06749305T patent/ES2330671T3/es active Active
- 2006-03-31 KR KR1020077025152A patent/KR101383493B1/ko not_active Expired - Fee Related
- 2006-03-31 MX MX2007012236A patent/MX2007012236A/es active IP Right Grant
- 2006-03-31 NZ NZ561936A patent/NZ561936A/en not_active IP Right Cessation
- 2006-03-31 DK DK06749305T patent/DK1888094T3/da active
- 2006-03-31 WO PCT/US2006/011768 patent/WO2006105345A2/en not_active Ceased
- 2006-03-31 EP EP06740117A patent/EP1871403B1/en active Active
- 2006-10-04 CN CNA2006800541222A patent/CN101415435A/zh active Pending
-
2007
- 2007-09-24 IL IL186200A patent/IL186200A/en not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/641,733 patent/US20100125054A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/964,516 patent/US8278267B2/en not_active Expired - Fee Related
-
2011
- 2011-05-20 US US13/112,290 patent/US8389477B2/en not_active Expired - Fee Related
-
2012
- 2012-09-28 US US13/631,577 patent/US20130225485A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/777,149 patent/US20130184213A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534606A5 (enExample) | ||
| Jeukendrup | Periodized nutrition for athletes | |
| Hickson | Malnutrition and ageing: This article is part of a series on ageing edited by Professor Chris Bulpitt | |
| Alsiö et al. | Feed-forward mechanisms: addiction-like behavioral and molecular adaptations in overeating | |
| Park et al. | Anti‐obesity effect of kimchi fermented with Weissella koreensis OK1‐6 as starter in high‐fat diet‐induced obese C57BL/6J mice | |
| Nagano et al. | Effect of dietary cellulose nanofiber and exercise on obesity and gut microbiota in mice fed a high-fat-diet | |
| Hao et al. | RYGB produces more sustained body weight loss and improvement of glycemic control compared with VSG in the diet-induced obese mouse model | |
| Lyon et al. | Is there a place for dietary fiber supplements in weight management? | |
| JP2010522185A5 (enExample) | ||
| Quinn et al. | Symposium review: Dairy-derived oligosaccharides—Their influence on host–microbe interactions in the gastrointestinal tract of infants | |
| EP2623120A3 (en) | Compositions comprising dietary fat complexer and methods for their use | |
| Chen et al. | Moderate intensity treadmill exercise alters food preference via dopaminergic plasticity of ventral tegmental area-nucleus accumbens in obese mice | |
| Freeland et al. | Acute effects of dietary fibre and glycaemic carbohydrate on appetite and food intake in healthy males | |
| Brunt et al. | Suppression of trimethylamine N-oxide with DMB mitigates vascular dysfunction, exercise intolerance, and frailty associated with a Western-style diet in mice | |
| JP2003529616A5 (enExample) | ||
| Hardin et al. | Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions | |
| Becker et al. | Novel nutritional and dietary approaches to weight loss for the prevention of cardiovascular disease: ketogenic diet, intermittent fasting, and bariatric surgery | |
| St-Jules et al. | A novel approach for managing protein-energy wasting in people with kidney failure undergoing maintenance hemodialysis: rationale and call for trials | |
| Hamidianshirazi et al. | Dietary acid load and chronic kidney disease | |
| RU2013129518A (ru) | Профилактика или лечение избыточной массы и ожирения у пациентов с диабетом 2 типа | |
| Nath et al. | Nonalcoholic fatty liver disease: time to take the bull by the horns | |
| US20140024674A1 (en) | Trpm5 inhibitors support body weight reduction without reducing food intake | |
| Shah et al. | Acquired zinc deficiency acrodermatitis associated with nephrotic syndrome | |
| Kugler et al. | Divergence in aerobic capacity influences hepatic and systemic metabolic adaptations to bile acid sequestrant and short-term high-fat/sucrose feeding in rats | |
| CN104379214A (zh) | 用于治疗代谢紊乱的野葛和植物甾醇 |